Difference between revisions of "Cancer antigen 125"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal | last1 = Jiang | first1 = K. | last2 = Tan | first2 = E. | last3 = Sayegh | first3 = Z. | last4 = Centeno | first4 = B. | last5 = Malafa | first5 = M. | last6 = Coppola | first6 = D. | title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. | journal = Appl Immunohistochem Mol Morphol | volume = | issue = | pages = | month = Apr | year = 2016 | doi = 10.1097/PAI.0000000000000368 | PMID = 27093451 }}</ref> | *[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal | last1 = Jiang | first1 = K. | last2 = Tan | first2 = E. | last3 = Sayegh | first3 = Z. | last4 = Centeno | first4 = B. | last5 = Malafa | first5 = M. | last6 = Coppola | first6 = D. | title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. | journal = Appl Immunohistochem Mol Morphol | volume = | issue = | pages = | month = Apr | year = 2016 | doi = 10.1097/PAI.0000000000000368 | PMID = 27093451 }}</ref> | ||
*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal | last1 = Lee | first1 = HI. | last2 = Kang | first2 = KH. | last3 = Cho | first3 = YM. | last4 = Lee | first4 = OJ. | last5 = Ro | first5 = JY. | title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. | journal = Arch Pathol Lab Med | volume = 130 | issue = 6 | pages = 871-4 | month = Jun | year = 2006 | doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 | PMID = 16740043 }}</ref> | *[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal | last1 = Lee | first1 = HI. | last2 = Kang | first2 = KH. | last3 = Cho | first3 = YM. | last4 = Lee | first4 = OJ. | last5 = Ro | first5 = JY. | title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. | journal = Arch Pathol Lab Med | volume = 130 | issue = 6 | pages = 871-4 | month = Jun | year = 2006 | doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 | PMID = 16740043 }}</ref> | ||
*[[Malignant mesothelioma]].<ref name=pmid27066377>{{cite journal |authors=Cheng X, Gou HF, Liu JY, Luo DY, Qiu M |title=Clinical significance of serum CA125 in diffuse malignant mesothelioma |journal=Springerplus |volume=5 |issue= |pages=368 |date=2016 |pmid=27066377 |pmc=4805673 |doi=10.1186/s40064-016-1998-7 |url=}}</ref><ref name=pmid9023557>{{cite journal |authors=Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A |title=Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression |journal=Histopathology |volume=30 |issue=1 |pages=49–56 |date=January 1997 |pmid=9023557 |doi=10.1046/j.1365-2559.1996.d01-562.x |url=}}</ref> | |||
==Positive/negative== | ==Positive/negative== | ||
Latest revision as of 19:52, 18 December 2024
Cancer antigen 125, abbreviated CA125 and CA-125, is a common immunostain and serum marker of disease. It is also known as mucin 16 and officially abbreviated MUC16.[1][2]
It is elevated in the serum in ovarian cancer and mildly or moderately elevated in endometriosis.
Positive
- Ovarian carcinoma ~ 75% of cases.[3]
- Serous carcinoma of the ovary ~ 95% of cases.[3]
- Pancreatic ductal adenocarcinoma.[4]
- Epithelioid sarcoma - reported.[5]
- Malignant mesothelioma.[6][7]
Positive/negative
- Cholangiocarcinoma - 30 +ve of 63 cases[8].
Usually negative
- Breast carcinoma ~15% of cases show weak focal positivity.[3]
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 606154
- ↑ URL: http://www.ncbi.nlm.nih.gov/gene/94025. Accessed on: 3 August 2016.
- ↑ 3.0 3.1 3.2 Tornos, C.; Soslow, R.; Chen, S.; Akram, M.; Hummer, AJ.; Abu-Rustum, N.; Norton, L.; Tan, LK. (Nov 2005). "Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.". Am J Surg Pathol 29 (11): 1482-9. PMID 16224215.
- ↑ Jiang, K.; Tan, E.; Sayegh, Z.; Centeno, B.; Malafa, M.; Coppola, D. (Apr 2016). "Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.". Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0000000000000368. PMID 27093451.
- ↑ Lee, HI.; Kang, KH.; Cho, YM.; Lee, OJ.; Ro, JY. (Jun 2006). "Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity.". Arch Pathol Lab Med 130 (6): 871-4. doi:10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2. PMID 16740043.
- ↑ Cheng X, Gou HF, Liu JY, Luo DY, Qiu M (2016). "Clinical significance of serum CA125 in diffuse malignant mesothelioma". Springerplus 5: 368. doi:10.1186/s40064-016-1998-7. PMC 4805673. PMID 27066377. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805673/.
- ↑ Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A (January 1997). "Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression". Histopathology 30 (1): 49–56. doi:10.1046/j.1365-2559.1996.d01-562.x. PMID 9023557.
- ↑ Higashi, M.; Yamada, N.; Yokoyama, S.; Kitamoto, S.; Tabata, K.; Koriyama, C.; Batra, SK.; Yonezawa, S. (2012). "Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type.". Pathobiology 79 (2): 101-6. doi:10.1159/000335164. PMID 22286058.